Thermo Fisher Scientific’s pharmaceutical services business has secured a series of multi-year contracts to relocate active pharmaceutical ingredient (API) and biologics production from Europe and Asia to U.S. facilities, CEO Marc Casper said on Tuesday. The agreements include three separate deals valued at a combined $150 million over five years, covering fill–finish capabilities in Cincinnati, Ohio, and cell-culture manufacturing in Carlsbad, California. Casper noted that demand for on-shore supply chains has driven a 25% year-over-year increase in new business inquiries, and that Thermo Fisher is allocating an additional $75 million in capex this fiscal year to expand clean-room capacity by 30% in key U.S. sites. Investors will closely watch utilization rates and margin contributions as production ramps up in the second half of 2026.

Thermo Fisher’s chief operating officer, Michel Lagarde, has informed the board of his intention to leave the company effective March 31, after more than eight years overseeing global manufacturing and supply-chain operations. Lagarde led the integration of five acquired businesses totaling $10 billion in aggregate deal value and drove a 15% reduction in operating costs through network optimization and digital-factory initiatives. The company has initiated an external search for his successor and will appoint an interim COO from its senior operations team. Management emphasized that ongoing expansion projects and the recently announced contracts will proceed without delay, but investors will monitor the transition process for any temporary disruptions to execution or capital projects.